Sutton Wealth Advisors Inc. Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

Sutton Wealth Advisors Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 1.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 21,638 shares of the company’s stock after selling 416 shares during the period. Johnson & Johnson accounts for about 1.7% of Sutton Wealth Advisors Inc.’s investment portfolio, making the stock its 14th biggest holding. Sutton Wealth Advisors Inc.’s holdings in Johnson & Johnson were worth $3,370,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Rather & Kittrell Inc. boosted its holdings in Johnson & Johnson by 2.0% in the second quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock valued at $481,000 after acquiring an additional 58 shares during the last quarter. Capital Square LLC boosted its holdings in Johnson & Johnson by 1.4% in the second quarter. Capital Square LLC now owns 4,245 shares of the company’s stock valued at $703,000 after acquiring an additional 58 shares during the last quarter. Wagner Wealth Management LLC boosted its holdings in Johnson & Johnson by 1.3% in the second quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock valued at $752,000 after acquiring an additional 59 shares during the last quarter. Chesapeake Wealth Management boosted its holdings in Johnson & Johnson by 0.7% in the second quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock valued at $1,522,000 after acquiring an additional 60 shares during the last quarter. Finally, RPG Investment Advisory LLC boosted its holdings in Johnson & Johnson by 1.2% in the second quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock valued at $807,000 after acquiring an additional 60 shares during the last quarter. 68.40% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE JNJ opened at $156.76 on Monday. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97. The firm has a market cap of $377.37 billion, a price-to-earnings ratio of 11.35, a PEG ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The stock’s 50-day simple moving average is $158.20 and its 200-day simple moving average is $158.73.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.35 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be issued a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 3.04%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on JNJ shares. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, February 6th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. Finally, Morgan Stanley reduced their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $176.14.

Read Our Latest Research Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.